arrow
J

Jae-Cheol Jo

university of ulsan
H指数:26
被引数:2,914

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Danburstotug, an anti-PD-L1 antibody, in relapsed/refractory extra-nodal natural killer/T-cell lymphoma: The phase 2 DISTINKT study

丹努斯妥昔单抗(Danburstotug),一种抗PD-L1抗体,在复发/难治性结外自然杀伤/T细胞淋巴瘤中的应用:DISTINKT二期研究

2026-09-050
PRE
Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: results of the multicenter KMMWP2201 study
2024-06-061
OAAI
Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study

靶向CD19近膜域的新型anti-CD19嵌合抗原受体T细胞产品对非霍奇金淋巴瘤的安全性和有效性: 一项首次人体研究

2023-12-098
OAAI
Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation
2023-08-222
OAAI
Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015)

白消安加美法仑与大剂量美法仑作为具有高风险特征的多发性骨髓瘤自体干细胞移植的预处理方案 (KMM 2015)

2023-07-012
PRE
Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation
2023-06-262
OAAI
An open label, dose escalation, phase 1 study of AT101, a novel CD19-directed CAR-T cell therapy targeting a membrane-proximal epitope of CD19, in patients with relapsed or refractory B cell non-Hodgkin lymphoma

在复发或难治性b细胞非霍奇金淋巴瘤患者中,针对CD19近膜表位的新型CD19-directed car-t细胞疗法AT101的开放标签,剂量递增,1期研究

2023-04-140
PRE
A Prospective Study of Preemptive Tenofovir Disoproxil Fumarate Therapy in HBsAg-Positive Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
2023-01-130
PRE
Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and 18F-FDG PET/CT
2021-12-0111
OAAI